Literature DB >> 29970235

Novel vaccines: Technology and development.

Sarita U Patil1, Wayne G Shreffler2.   

Abstract

The development and widespread use of vaccines, which are defined by the World Health Organization as "biological preparations that improve immunity to a particular disease," represents one of the most significant strides in medicine. Vaccination was first applied to reduce mortality and morbidity from infectious diseases. The World Health Organization estimates that vaccines prevent 2 to 3 million human deaths annually, and these numbers would increase by at least 6 million if all children received the recommended vaccination schedule. However, the origins of allergen immunotherapy share the same intellectual paradigm, and subsequent innovations in vaccine technology have been applied beyond the prevention of infection, including in the treatment of cancer and allergic diseases. This review will focus on how new and more rational approaches to vaccine development use novel biotechnology, target new mechanisms, and shape the immune system response, with an emphasis on discoveries that have direct translational relevance to the treatment of allergic diseases.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Vaccines; antibodies; immunotherapy; sequencing

Year:  2018        PMID: 29970235      PMCID: PMC6311446          DOI: 10.1016/j.jaci.2018.05.021

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  96 in total

1.  Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines.

Authors:  J E SALK; U KRECH; J S YOUNGNER; B L BENNETT; L J LEWIS; P L BAZELEY
Journal:  Am J Public Health Nations Health       Date:  1954-05

2.  Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses.

Authors:  W M HAMMON; L L CORIELL; P F WEHRLE; J STOKES
Journal:  J Am Med Assoc       Date:  1953-04-11

3.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Authors:  M Pizza; V Scarlato; V Masignani; M M Giuliani; B Aricò; M Comanducci; G T Jennings; L Baldi; E Bartolini; B Capecchi; C L Galeotti; E Luzzi; R Manetti; E Marchetti; M Mora; S Nuti; G Ratti; L Santini; S Savino; M Scarselli; E Storni; P Zuo; M Broeker; E Hundt; B Knapp; E Blair; T Mason; H Tettelin; D W Hood; A C Jeffries; N J Saunders; D M Granoff; J C Venter; E R Moxon; G Grandi; R Rappuoli
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

6.  Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.

Authors:  S A Kalams; S P Buchbinder; E S Rosenberg; J M Billingsley; D S Colbert; N G Jones; A K Shea; A K Trocha; B D Walker
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection.

Authors:  Mark J Boaz; Anele Waters; Shahed Murad; Philippa J Easterbrook; Annapurna Vyakarnam
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

8.  Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; S Jiang; P L Li; T W Baba; D C Montefiori; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; R M Ruprecht
Journal:  J Med Primatol       Date:  2002-06       Impact factor: 0.667

9.  Summary report of the experiments conducted at Pouilly-le-Fort, near Melun, on the anthrax vaccination, 1881.

Authors:  Louis Pasteur
Journal:  Yale J Biol Med       Date:  2002 Jan-Feb

10.  Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types.

Authors:  A B SABIN; W A HENNESSEN; J WINSSER
Journal:  J Exp Med       Date:  1954-06-01       Impact factor: 14.307

View more
  3 in total

1.  The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization.

Authors:  Thomas Ebensen; Simon Delandre; Blair Prochnow; Carlos A Guzmán; Kai Schulze
Journal:  Front Cell Infect Microbiol       Date:  2019-02-19       Impact factor: 5.293

Review 2.  Peptide-Based Vaccination Therapy for Rheumatic Diseases.

Authors:  Bin Wang; Shiju Chen; Qing Zheng; Yuan Liu; Guixiu Shi
Journal:  J Immunol Res       Date:  2020-03-18       Impact factor: 4.818

3.  Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.

Authors:  Ganesh Kumraj; Sarang Pathak; Sanket Shah; Piyali Majumder; Jainendra Jain; Davender Bhati; Sarmad Hanif; Sushmita Mukherjee; Syed Ahmed
Journal:  Hum Vaccin Immunother       Date:  2022-01-27       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.